FUNDAMENTALS
EdgeFII/DII
TORNTPHARMTorrent Pharmaceuticals
₹4,689.50+1.70%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
TORNTPHARMNSE · EquityPharmaceuticals

Torrent Pharmaceuticals

ISIN
INE685A01028
Instrument key
NSE_EQ|INE685A01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹4,689.50+78.50 · +1.70%
Day rangecircuit ₹4,220.60 – ₹5,158.40
4,611.20
4,689.50

as of 22/11/2026, 1:22:50 pm

Open
₹4,618.90
Day high
₹4,689.50
Day low
₹4,611.20
Prev. close
₹4,611.00
Volume
2.00 L
VWAP
₹4,659.46

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

6 months · daily candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 6M
+4.53%
4,486.20 → 4,689.50
Period high
₹5,250.00
3/8/2026
Period low
₹4,240.30
2/6/2026
From high
-10.68%
+10.59% from low
Avg volume
4.87 L
6.14 Cr total
Volatility · ann.
22.6%
126 candles · 63 up / 63 down
20 Nov 2026O 4,618.90H 4,689.50L 4,611.20C 4,689.50Vol 2.00 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data126 rows of open, high, low, close and volumeShowHide
20 Nov 20264,618.904,689.504,611.204,689.50+1.53%78.302.00 L
19 Nov 20264,604.004,670.304,592.604,611.00+0.15%77.702.39 L
18 Nov 20264,668.804,699.504,610.704,610.70-1.24%88.802.50 L
17 Nov 20264,653.104,686.504,626.504,668.80+0.34%60.002.68 L
16 Nov 20264,708.504,732.304,660.004,691.20-0.37%72.302.46 L
13 Nov 20264,680.004,741.704,655.104,670.00-0.21%86.602.45 L
12 Nov 20264,761.004,765.104,660.004,727.20-0.71%105.102.85 L
11 Nov 20264,805.004,805.004,740.004,761.00-0.92%65.003.48 L
9 Nov 20264,812.504,835.004,734.504,780.00-0.68%100.504.03 L
8 Nov 20264,784.004,800.004,750.104,773.00-0.23%49.9013.1K

Historical price and volume data · Showing 1–10 of 126

1 / 13

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

85.15
Company
85.15
Sector
-45.69

Worse than sector by 286%

P/B

Price ÷ book value per share

9.73
Company
9.73
Sector
4.2

Worse than sector by 132%

ROA

Net income ÷ total assets

4.7%
Company
4.7%
Sector
1.19%

Better than sector by 295%

ROE

Net income ÷ shareholders' equity

11.42%
Company
11.42%
Sector
-0.4%

Better than sector by 2955%

ROCE

EBIT ÷ capital employed

11.37%
Company
11.37%
Sector
15.44%

Worse than sector by 26%

Quick Ratio

Liquid assets ÷ current liabilities

0.75
Company
0.75
Sector
4.78

Worse than sector by 84%

EV/EBITDA

Enterprise value ÷ EBITDA

34.12
Company
34.12
Sector
22.9

Worse than sector by 49%

04/Business

About the company

Sector: Pharmaceuticals

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.

Sector market cap (INR)
₹1,78,727 Cr

reported in crore

Sector market cap (USD)
$19.86B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Standalone income statement

Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Mar 2026
₹11,352 Cr
+16.86% vs Mar 2025
Net profit · Mar 2026
₹2,034 Cr
+7.73% vs Mar 2025
Operating margin
24.0%
was 26.9%
Revenue CAGR · 4p
13.4%
profit 24.6% · op 19.9%
Filed order
Revenue11,3529,7148,6247,777
Revenue growthreported16.9%12.6%10.9%—
Operating profit2,7212,6101,9171,577
Operating profit growthreported4.3%36.1%21.6%—
Operating marginderived24.0%26.9%22.2%20.3%
Net profit2,0341,8881,3571,052
Net profit growthreported7.7%39.1%29.0%—
Net marginderived17.9%19.4%15.7%13.5%
EPS — basic₹/share, annual64.7555.7940.1031.07

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue10,7129,6828,5337,695
Other Income18329182
Total Revenue10,7309,7148,6247,777
Total Expenses7,7637,0806,7086,200
Profit Before Tax2,8972,6101,9171,577
Tax705722559526
Profit After Tax2,1921,8881,3571,051
EPS - Basic64.7555.7940.1031.07
EPS - Diluted64.7555.7940.1031.07

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Standalone balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹25,814 Cr
+101.01% YoY
Total liabilities
₹17,361 Cr
Net worth
₹8,452 Cr
Liabilities ÷ assets
67.3%
lower means a lighter balance sheet
Filed order
Total assets25,81412,84212,37712,872
Total liabilities17,3615,2495,5486,416
Net worthderived8,4527,5936,8296,456
Liabilities ÷ assetsderived67.3%40.9%44.8%49.8%
Asset growthderived101.0%3.8%-3.8%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets20,9228,4938,6368,945
Current Assets4,8914,3493,7413,927
Total Assets25,81412,84212,37712,872
Current Liabilities4,5892,9802,9893,409
Net Current Asset3021,369752518
Non-Current Liabilities12,7732,2702,5593,007
Equity Capital8,4527,5936,8296,456
Total Equity & Liabilities25,81412,84212,37712,872

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Standalone cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹2,731 Cr
+6.07% YoY
Investing
-₹12,990 Cr
Financing
₹10,225 Cr
Free cash flow
-₹10,259 Cr
operating + investing
Filed order
Operating activities2,7312,5752,8932,265
Operating changereported6.1%-11.0%27.7%—
Investing activities-12,990-470-296-2,384
Investing changereported-2663.3%-58.8%87.6%—
Financing activities10,225-2,104-2,57881
Financing changereported585.9%18.4%-3292.4%—
Net cash flowderived-34-019-38
Free cash flowoperating + investing-10,2592,1042,597-119

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,8972,6101,9171,577
Income before WC changes3,9133,5802,8742,568
Change in Assets-467-638213-51
Change in Liabilities112313122
Change in WC-466-515344-30
Cash flow from Operations2,7312,5752,8932,265
Cash flow from Investing-12,990-470-296-2,384
Cash flow from Financing10,225-2,104-2,57881
Total Cash Flow-34-019-38
Cash (Start of the year)1051058565
Cash (End of the year)7110510585

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
60.78%
0.00 pts QoQ
FII
17.22%
-0.75 pts QoQ
DII (other)
4.64%
+0.05 pts QoQ
Mutual funds
8.82%
+0.55 pts QoQ
Retail & others
8.54%
+0.16 pts QoQ
Filed order
Promoters60.8%60.8%68.3%68.3%
FII17.2%18.0%15.4%16.2%
DII (other)4.6%4.6%4.9%4.6%
Mutual funds8.8%8.3%4.9%4.5%
Retail & others8.5%8.4%6.4%6.5%
Promoters — QoQ changepts, derived0.0%-7.5%0.0%—
FII — QoQ changepts, derived-0.8%2.5%-0.7%—
DII (other) — QoQ changepts, derived0.0%-0.3%0.3%—
Mutual funds — QoQ changepts, derived0.6%3.3%0.5%—
Retail & others — QoQ changepts, derived0.2%2.0%-0.0%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹9.00180.0%29 May 202629 May 202622 May 2026
DividendInterim₹29.00580.0%18 Feb 202619 Feb 202604 Feb 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.